#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Immunodeficiency common variable Congenital cystic kidney disease Congenital growth hormone deficiency Myelofibrosis Mastocytosis Cutaneous T-cell lymphoma Chondrosarcoma metastatic Colorectal adenocarcinoma Partial lipodystrophy Hepatic cirrhosis Staphylococcal infection Loss of consciousness Phenylketonuria Haematological malignancy Metachromatic leukodystrophy More trials…

    Learn about Rare Diseases

    Adrenocortical carcinoma – Treatment Hepatoblastoma – Diagnostics Retinitis pigmentosa Hereditary optic atrophy – Treatment Aicardi-Goutieres syndrome – Treatment Breast angiosarcoma metastatic – Treatment Hereditary hypophosphataemic rickets Fabry’s disease – Treatment Behcet’s syndrome – Treatment Synovial sarcoma metastatic – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    HSP-CAR19M Tianeptine Sulpiride Sodium 2-Hydroxylinoleate Nefopam Hydrochloride Cannabis Sativa Flower Ibrexafungerp Vibozilimod Artemisia Vulgaris Prednisolone Pf-07220060 Monohydrate Deutivacaftor Wve-006 Magnesium Stearate Florbetapir (18F) Dexrazoxane Pembrolizumab Rbl016.2 Ioflupane (123I) Mps-200 More therapies…

    Learn about Your Condition

    Malignant peritoneal neoplasm Laparotomy Carotid artery occlusion Leber's congenital amaurosis HER2 positive gastric cancer Gender dysphoria Critical illness Immune-mediated renal disorder Acute promyelocytic leukaemia Spermatocele Femur fracture Vascular malformation Corneal graft rejection Mesothelioma malignant Cervix carcinoma stage III More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Retinal vein occlusion

  • A study to evaluate the safety and effectiveness of ANXV in patients with diabetic retinopathy or retinal vein occlusion

    Recruiting

    2 1 1
    Investigated Diseases:
    • Diabetic retinopathy
    • Retinal vein occlusion
    Investigated Drugs:
    • ANXV
    Germany

  • Study on the Effect of Aflibercept Injections in Patients with Central Retinal Vein Occlusion (CRVO) and Spontaneous Retinal Arterial Pulsations (SRAPs)

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Retinal vein occlusion
    Investigated Drugs:
    • Aflibercept
    France

  • Study on Ranibizumab Injections and Laser Treatment for Macular Edema in Central Retinal Vein Occlusion Patients

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Macular oedema
    • Retinal vein occlusion
    Investigated Drugs:
    • Ranibizumab
    Austria Germany

  • Study on the Safety and Use of AVT06 (Aflibercept) for Patients with Chorioretinal Vascular Diseases

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Choroidal neovascularisation
    • Diabetic retinopathy
    • Retinal vein occlusion
    Investigated Drugs:
    • Aflibercept
    Latvia

  • Study on the Effectiveness and Safety of Aflibercept for Patients with Vision Loss Due to Macular Edema from Retinal Vein Blockage

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Macular oedema
    • Retinal vein occlusion
    Investigated Drugs:
    • Aflibercept
    • Fluorescein Sodium
    Austria Bulgaria Czechia Estonia France Germany +8

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!